Vitamin K antagonists vs no VKA
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in all‐cause mortality (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
- Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes onlyRR 0.99 [0.64, 1.55]4 studies · 701 participantsLow